menu search

Anti-vegf market to cross us$ 34.9 billion revenues between 2023 and 2033 – persistence market research

Increasing Government Investments in Development of Efficient Healthcare Systems Aiding Demand Growth for vegf...

April 18, 2023, 12:42 pm

Panavance therapeutics announces positive preclinical data demonstrating gp-2250 single-agent and combination activity for the treatment of ovarian cancer

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 GP-2250’s antineoplastic effects on ovarian cancer cells i...

April 17, 2023, 12:05 pm

Aravive to present positive updated data from phase 1b trial of batiraxcept in combination with cabozantinib for treatment of clear cell renal cell carcinoma at the 2023 asco genitourinary (gu) cancer

HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted...

February 13, 2023, 5:00 pm

Aravive to present positive updated data from phase 1b trial of batiraxcept in combination with cabozantinib for treatment of clear cell renal cell carcinoma at the 2023 asco genitourinary (gu) cancer

HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted...

February 13, 2023, 5:00 pm

Aravive to present positive updated data from phase 1b trial of batiraxcept in combination with cabozantinib for treatment of clear cell renal cell carcinoma at the 2023 asco genitourinary (gu) cancer

HOUSTON, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted...

February 13, 2023, 5:00 pm

Biopharma co.’s shares triple in value on us$5b license deal

Source: Streetwise Reports (12/7/22) Summit Therapeutics Inc. shares traded 194% higher yesterday after the company reported it entered into an in-lic...

December 8, 2022, 1:30 pm

Kodiak (kod) completes enrolling patients in retina-based studies

Kodiak Sciences (KOD) has enrolled more than 900 patients in two phase III studies evaluating its vegf ...

February 4, 2022, 1:45 pm

Kodiak (kod) completes enrolling patients in retina-based studies

Kodiak Sciences (KOD) has enrolled more than 900 patients in two phase III studies evaluating its vegf ...

February 4, 2022, 1:45 pm

Kodiak (kod) completes enrolling patients in retina-based studies

Kodiak Sciences (KOD) has enrolled more than 900 patients in two phase III studies evaluating its vegf ...

February 4, 2022, 1:45 pm

Unity biotechnology stock falls after updated data from wet amd candidate

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w...

October 5, 2021, 3:52 pm

Unity biotechnology stock falls after updated data from wet amd candidate

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w...

October 5, 2021, 3:52 pm

Unity biotechnology stock falls after updated data from wet amd candidate

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w...

October 5, 2021, 3:52 pm

Unity biotechnology stock falls after updated data from wet amd candidate

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w...

October 5, 2021, 3:52 pm

Unity biotechnology stock falls after updated data from wet amd candidate

Unity Biotechnology Inc (NASDAQ: UBX) announced 12-week data from its ongoing Phase 1 safety study of UBX1325 in diabetic macular edema (DME) and w...

October 5, 2021, 3:52 pm


Search within

Pages Search Results: